Jun 22, 2018
Lilly Completes Acquisition of ARMO BioSciences
May 10, 2018
Lilly Announces Agreement To Acquire ARMO BioSciences
Jan 25, 2018
ARMO BioSciences Announces Pricing of Initial Public Offering
Dec 29, 2017
ARMO BioSciences Files Registration Statement for Proposed Initial Public Offering
Dec 09, 2017
ARMO BioSciences Presents Data from its Phase 1b Trial in Non-Small Cell Lung Cancer at ESMO Immuno Oncology Congress 2017
Dec 08, 2017
ARMO BioSciences Presents Efficacy Data from its Phase 1b Trial in Patients with Metastatic Renal Cell Carcinoma at ESMO Immuno-Oncology Congress 2017
Nov 28, 2017
ARMO BioSciences Appoints Herb Cross as Chief Financial Officer
Oct 09, 2017
ARMO BioSciences Appoints Immuno-Oncology Industry Veteran Joseph Leveque, M.D., as Chief Medical Officer
Sep 09, 2017
ARMO BioSciences's Phase 1b Trials Demonstrate Continued Promising Response Rates and Survival in Patients with Advanced Pancreatic Cancer, NSCLC, and RCC
Aug 29, 2017
ARMO BioSciences Raises $67 Million in a Series C-1 Financing
Jun 29, 2017
ARMO BioSciences Presents Clinical Data on Immunotherapy AM0010 in Advanced Pancreatic Cancer at ESMO World Congress on Gastrointestinal Cancer 2017
Jun 28, 2017
ARMO BioSciences Appoints Naiyer A. Rizvi, M.D. to Board of Directors
Jun 03, 2017
ARMO BioSciences Announces Promising Response Rates and Survival Data in Patients with Advanced NSCLC and RCC from Phase 1/1b Trial for Immunotherapy AM0010 with Checkpoint Inhibitors
Jun 03, 2017
ARMO BioSciences Announces Encouraging Survival Data Observed in Patients with Advanced Pancreatic Cancer in Phase 1/1b Trial of Immunotherapy AM0010
May 30, 2017
ARMO BioSciences to Present at the Jefferies 2017 Global Healthcare Conference